Skip to main content

Public mistrust linked to drop in deceased donor organ donations and kidney transplants

WASHINGTON (AP) — Organ donations from the recently deceased dropped last year for the first time in over a decade, resulting in fewer kidney transplants, according to an analysis issued Wednesday that pointed to signs of public mistrust in the lifesaving system.

More than 100,000 people in the U.S. are on the list for an organ transplant. The vast majority of them need a kidney, and thousands die waiting every year.

The nonprofit Kidney Transplant Collaborative analyzed federal data and found 116 fewer kidney transplants were performed last year than in 2024. That small difference is a red flag because the analysis traced the decline to some rare but scary reports of patients prepared for organ retrieval despite showing signs of life.

Those planned retrievals were stopped and the U.S. is developing additional safeguards for the transplant system, which saves tens of thousands of lives each year. But it shook public confidence, prompting some people to remove their names from donor lists.

Dr. Andrew Howard, who leads the Kidney Transplant Collaborative, said last year’s dip in kidney transplants would have been larger except for a small increase — about 100 — in transplants from living donors, when a healthy person donates one of their kidneys to someone in need. The collaborative advocates for increased living donations, which make up a fraction of the roughly 28,000 yearly kidney transplants.

With the exception of 2020, when the COVID-19 pandemic was raging, organ transplants have been rising year-to-year. Last year’s decline in deceased donors didn’t translate into fewer transplants overall: There were just over 49,000 compared with 48,150 in 2024. Transplants of hearts, livers and lungs continued to see gains, according to federal data. Howard said that was likely due to differences in how various organs are evaluated and allocated for transplant.

The Association of Organ Procurement Organizations wasn’t involved in Wednesday’s analysis but expressed alarm, calling on its members, hospitals and federal regulators “to unite in restoring public trust and strengthening this critical system.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue

SANTIAGO, Chile (AP) — When a rare but deadly rodent-borne virus struck passengers on a cruise ship and seemed to be spreading, there were no treatments for those who fell ill and no vaccines to protect others. That was the case even though it wasn't a novel germ that the world had never seen before, like the virus that caused the coronavirus pandemic. It was a hantavirus, one of a family of viruses that have been known for decades and are thought to exist around the world. Teams of researchers, including in Chile, Argentina and the United States, have long been trying to find and develop drugs and vaccines. But because the viruses are relatively rare and don't spread easily between people, there hasn't been enough sustained investment by governments, global health groups, or drug companies to pay for the extensive safety and efficacy testing needed to make them available. Still, there have been some promising developments. Researchers on Wednesday published a hint that a drug used for an autoimmune disease may help hantavirus patients fight off the most deadly symptoms.
Read Next Story